Tenofovir vs. d4T

This article presents the much-anticipated results Gilead Study 903, a manufacturer-sponsored study conducted at 81 sites in South America, Europe, and the U.S. A total of 602 antiretroviral-naive patients were randomized to receive tenofovir once daily (299 patients) or d4T twice daily (303 patients), both in combination with 3TC + efavirenz. The two groups had comparable baseline demographics, mean viral loads (81,300 copies/mL in both groups), and mean CD4 counts (276 cells/mm3 and 283 cells/mm3 in the tenofovir and 3TC groups, respectively). Slightly more than 40% of the …